Quarterly report pursuant to Section 13 or 15(d)

LICENSE AGREEMENT WITH CURIA

v3.23.1
LICENSE AGREEMENT WITH CURIA
3 Months Ended
Mar. 31, 2023
License Agreement With Curia  
LICENSE AGREEMENT WITH CURIA

NOTE 11 – LICENSE AGREEMENT WITH CURIA

 

On December 12, 2022, the Company entered into an exclusive license agreement with Curia for the development of three humanized murine mAbs for the treatment or prophylaxis of SARS-CoV-2 infection. We believe that the licensing of these mAbs strengthens our pipeline of next-generation therapeutics to treat COVID-19, which is caused by SARS-CoV-2. As consideration for entering into the License Agreement, we paid a license fee of approximately $0.4 million to Curia. The License Agreement also provides for single-digit royalties and contingent milestone payments. As of March 31, 2023, other than the upfront fee, no payments have been accrued or paid in relation to this agreement.